Hematologic Neoplasms
"Hematologic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Descriptor ID |
D019337
|
MeSH Number(s) |
C04.588.448 C15.378.400
|
Concept/Terms |
Hematologic Neoplasms- Hematologic Neoplasms
- Hematologic Malignancy
- Neoplasms, Hematologic
- Hematologic Neoplasm
- Neoplasm, Hematologic
- Hematological Neoplasms
- Hematological Neoplasm
- Neoplasm, Hematological
- Neoplasms, Hematological
- Malignancies, Hematologic
- Malignancy, Hematologic
- Hematologic Malignancies
- Hematological Malignancies
- Hematological Malignancy
- Malignancies, Hematological
- Malignancy, Hematological
Hematopoietic Neoplasms- Hematopoietic Neoplasms
- Neoplasms, Hematopoietic
- Hematopoietic Neoplasm
- Neoplasm, Hematopoietic
- Hematopoietic Malignancies
- Hematopoietic Malignancy
- Malignancies, Hematopoietic
- Malignancy, Hematopoietic
|
Below are MeSH descriptors whose meaning is more general than "Hematologic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Hematologic Neoplasms".
This graph shows the total number of publications written about "Hematologic Neoplasms" by people in this website by year, and whether "Hematologic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 2 | 1 | 3 | 2002 | 1 | 2 | 3 | 2004 | 0 | 1 | 1 | 2006 | 0 | 3 | 3 | 2007 | 2 | 1 | 3 | 2008 | 0 | 1 | 1 | 2009 | 1 | 4 | 5 | 2010 | 7 | 0 | 7 | 2011 | 7 | 2 | 9 | 2012 | 4 | 0 | 4 | 2013 | 3 | 1 | 4 | 2014 | 3 | 1 | 4 | 2015 | 6 | 2 | 8 | 2016 | 8 | 5 | 13 | 2017 | 7 | 1 | 8 | 2018 | 7 | 2 | 9 | 2019 | 2 | 1 | 3 | 2020 | 4 | 0 | 4 | 2021 | 7 | 0 | 7 | 2022 | 3 | 0 | 3 | 2023 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Hematologic Neoplasms" by people in Profiles.
-
Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 05; 21(5):503-513.
-
Austin RJ, Straube J, Halder R, Janardhanan Y, Bruedigam C, Witkowski M, Cooper L, Porter A, Braun M, Souza-Fonseca-Guimaraes F, Minnie SA, Cooper E, Jacquelin S, Song A, Bald T, Nakamura K, Hill GR, Aifantis I, Lane SW, Bywater MJ. Oncogenic drivers dictate immune control of acute myeloid leukemia. Nat Commun. 2023 04 14; 14(1):2155.
-
Berkman AM, Andersen CR, Hildebrandt MAT, Livingston JA, Green AL, Puthenpura V, Peterson SK, Milam J, Miller KA, Freyer DR, Roth ME. Risk of early death in adolescents and young adults with cancer: a population-based study. J Natl Cancer Inst. 2023 Apr 11; 115(4):447-455.
-
Dawson MA, Borthakur G, Huntly BJP, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass JL, Kamdar M, Mateos MV, Tovar N, Yeh P, Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A, Kremer BE, Dickinson M. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2023 02 16; 29(4):711-722.
-
Kent A, Pollyea DA. Top advances of the year: Leukemia. Cancer. 2023 04 01; 129(7):981-985.
-
Faruqi AJ, Ligon JA, Borgman P, Steinberg SM, Foley T, Little L, Mackall CL, Lee DW, Fry TJ, Shalabi H, Brudno J, Yates B, Mikkilineni L, Kochenderfer J, Shah NN. The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. Blood Adv. 2022 12 13; 6(23):6040-6050.
-
Ahmed M, Pollyea DA. Lower intensity regimens for acute myeloid leukemia: opportunities and challenges. Leuk Lymphoma. 2023 01; 64(1):66-70.
-
Wadugu BA, Nonavinkere Srivatsan S, Heard A, Alberti MO, Ndonwi M, Liu J, Grieb S, Bradley J, Shao J, Ahmed T, Shirai CL, Khanna A, Fei DL, Miller CA, Graubert TA, Walter MJ. U2af1 is a haplo-essential gene required for hematopoietic cancer cell survival in mice. J Clin Invest. 2021 11 01; 131(21).
-
Wagner JE, Ballen KK, Zhang MJ, Allbee-Johnson M, Karanes C, Milano F, Verneris MR, Eapen M, Brunstein CG. Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. Blood Adv. 2021 10 26; 5(20):4064-4072.
-
Horwitz ME, Stiff PJ, Cutler C, Brunstein C, Hanna R, Maziarz RT, Rezvani AR, Karris NA, McGuirk J, Valcarcel D, Schiller GJ, Lindemans CA, Hwang WYK, Koh LP, Keating A, Khaled Y, Hamerschlak N, Frankfurt O, Peled T, Segalovich I, Blackwell B, Wease S, Freedman LS, Galamidi-Cohen E, Sanz G. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021 10 21; 138(16):1429-1440.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|